Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

COCH vs HWH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COCH Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–3 Matrix Metrics)

COCH Overall Winner 6-Pillar Tally: COCH 2 – 2 HWH (2 Tie) Matrix Metrics: COCH 4 – 3 HWH

As of Nov 20, 2026, Envoy Medical, Inc. (COCH) is the stronger overall head-to-head candidate over HWH International Inc. (HWH) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas HWH carries 37.4/100 (SELL) at $2.68 (N/M Forward P/E, -356.2% operating margin).

  • Composite vs. Pillar Nuance: While HWH currently prints a higher short-term Unified Composite Score (37.4/100 SELL vs. COCH 35.1/100 SELL), COCH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-10261.0% vs. -356.2% operating margin) and revenue trajectory (+57.1% vs. -79.3% YoY).
  • Defensive Composite Rating Caution: Although COCH compares more favorably head-to-head, both COCH (35.1/100 SELL) and HWH (37.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCH vs HWH
COCH NASDAQ Head-to-Head Winner
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12
HWH NASDAQ
HWH International Inc. Common Stock
Wholesale-Drugs, Proprietaries & Druggists' Sundries
$2.68
+15.02% 1D
Market Cap $18.0M
TTM Revenue $389,738
Forward P/E N/M
Beta / 30D Vol 1.02β · 88% Vol
Unified Composite Score
37.4 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (15.7% over 20 days), RSI 75
RSI-14: 74.5 · SMA20: $2.02 · SMA50: $1.71

6-Pillar Scorecard Institutional Category Breakdown (COCH 2 – 2 HWH)

Columns: Metric · COCH · HWH
1. Valuation Multiples HWH
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 119.2x 42.9x
2. Growth & Scale COCH
Revenue Growth (YoY) +57.1% -79.3%
Earnings Growth (YoY) +0.0% +181.1%
TTM Revenue (USD) $231,000 $389,738
Market Cap $51.9M $18.0M
3. Profitability & Quality HWH
Gross Margin N/A N/A
Operating Margin -10261.0% -356.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -87.0%
4. Balance Sheet & Cash Flow COCH
Cash Generation (TTM) -$21M -$955,254
Cash Flow Margin N/A N/A
Net Cash / Leverage $24M Net Cash $1.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Restaurants Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCH (4) vs HWH (3)
Institutional Metric COCH HWH Criterion Row Edge
Market Capitalization
Scale
$51.9M $18.0M Larger Scale COCH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+57.1% -79.3% Higher Growth COCH
Operating Margin (TTM)
Profitability
-10261.0% -356.2% Higher Margin HWH
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -87.0% Higher ROE COCH
52-Week Range Position
Momentum
89% ($0–$7) 80% ($1–$3) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
4.94β · 3352% Vol 1.02β · 88% Vol Lower Realized Risk HWH
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 37.4 / 100 (SELL) Higher Composite HWH
Trailing 12M Revenue (USD)
Operating Scale
$231,000 $389,738 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 119.2x EV/Rev N/M PEG · 42.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($24M Net Cash) -$955,254 ($1.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HWH +27.69 pp
COCH: -5.32% · HWH: +22.37%
3M Horizon HWH +81.11 pp
COCH: +7.62% · HWH: +88.73%
6M Horizon HWH +105.55 pp
COCH: -8.49% · HWH: +97.06%
1Y Horizon HWH +79.83 pp
COCH: +0.04% · HWH: +79.87%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCH Revenue HWH Revenue COCH Op. Margin HWH Op. Margin Margin Leader
FY2022 $0M N/A -3673.4% N/A COCH
FY2023 $0M $0M -5809.8% -91257.8% COCH
FY2024 $0M $0M -8558.2% -219.4% HWH
FY2025 $0M $0M -9240.7% -303.4% HWH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HWH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HWH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HWH Moat Profile Cyclical / Execution-Driven Positioning
Restaurants Operator
Competes within the Restaurants value chain with $18.0M market capitalization and -356.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCH vs HWH Key Questions & Quantitative Answers

As of Nov 20, 2026, Envoy Medical, Inc. (COCH) is the stronger overall head-to-head candidate over HWH International Inc. (HWH) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas HWH carries 37.4/100 (SELL) at $2.68 (N/M Forward P/E, -356.2% operating margin). Composite vs. Pillar Nuance: While HWH currently prints a higher short-term Unified Composite Score (37.4/100 SELL vs. COCH 35.1/100 SELL), COCH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-10261.0% vs. -356.2% operating margin) and revenue trajectory (+57.1% vs. -79.3% YoY). Defensive Composite Rating Caution: Although COCH compares more favorably head-to-head, both COCH (35.1/100 SELL) and HWH (37.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

COCH leads the Growth & Scale pillar: COCH posts +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin), compared with HWH at -79.3% YoY revenue growth and +181.1% YoY earnings growth on $389,738 TTM revenue (N/A gross margin, -356.2% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), COCH cumulative revenue shifted N/A while HWH shifted N/A. In operating R&D and SG&A reinvestment, COCH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HWH.

HWH screens cheaper on headline valuation multiples. COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin), whereas HWH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 42.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCH (0.0% ROE) versus HWH (-87.0% ROE) capital efficiency.

In options market volatility and institutional positioning, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk). By comparison, HWH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.02β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.